IFOM ETS - The AIRC Institute of Molecular Oncology
12
5
5
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
8%
1 trials in Phase 3/4
33%
1 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status
Role: lead
The Sagittarius Trial
Role: lead
Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel
Role: lead
ALFAOMEGA Master Observational Trial
Role: lead
A Retrospective Protocol Empowering Precision Research in Colorectal Cancer (ALFAOMEGA-RETRÒ)
Role: lead
A Master Protocol Empowering Mechanobiology Translation Research in Breast Cancer
Role: lead
Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial
Role: lead
Fasting-mimicking Diet and Longevity Diet, Body Composition and Aging
Role: collaborator
FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction
Role: collaborator
Calorie Restriction With or Without Metformin in Triple Negative Breast Cancer
Role: collaborator
Clinical Feasibility and Efficacy of Intermittent Use of a Fasting Mimicking Diet in the Treatment of Type 2 Diabetes
Role: collaborator
Treat_CCM: Propranolol in Familial Cerebral Cavernous Malformation
Role: collaborator
All 12 trials loaded